J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Effect of antiviral treatment on the shedding of HIV-1 in semen.
Pietro Vernazza,Bruce L. Gilliam,Markus Flepp,John R. Dyer,Andreas C. Frank,Susan A. Fiscus,Myron S. Cohen,Joseph J. Eron +7 more
TL;DR: Treatment-induced changes of HIV RNA concentration in blood are generally associated with a corresponding change in seminal HIV RNA, and potent antiretroviral therapy might reduce the spread of HIV-1.
Journal ArticleDOI
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
Ronald J. Bosch,Justin Ritz,Jason M. Hataye,Evgenia Aga,Randall Tressler,Stephen W. Mason,Carey Hwang,Dennis M. Grasela,Neelanjana Ray,Josh C Cyktor,John M. Coffin,Edward P. Acosta,Richard A. Koup,John W. Mellors,Joseph J. Eron +14 more
TL;DR: In this first evaluation of an immunologic checkpoint inhibitor in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions appeared to enhance HIV- 1-specific immunity in a subset of participants.
Journal ArticleDOI
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Laurence T. Rimsky,Johan Vingerhoets,Veerle Van Eygen,Joseph J. Eron,Bonaventura Clotet,Annemie Hoogstoel,Katia Boven,Gaston Picchio +7 more
TL;DR: VF and treatment-emergent reverse transcriptase RAMs were similar at low baseline VL but more frequent at high baselineVL in rilpivirine-treated than in efavirenz-treated patients, and the frequent emergence of E138K, especially in combination with M184I, is a unique finding of these trials.
Journal ArticleDOI
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
Mark T. Nelson,Keikawus Arastéh,Bonaventura Clotet,David A. Cooper,Keith Henry,Christine Katlama,Jacob Lalezari,Adriano Lazzarin,Julio S. G. Montaner,Mary O'Hearn,Peter J. Piliero,Jacques Reynes,Benoit Trottier,Sharon Walmsley,Calvin Cohen,Calvin Cohen,Joseph J. Eron,Daniel R. Kuritzkes,Joep M. A. Lange,Hans Jürgen Stellbrink,Hans Jürgen Stellbrink,Jean François Delfraissy,Neil Buss,Lucille Donatacci,Cynthia Wat,Lynn Smiley,Martin Wilkinson,Adeline Valentine,Denise Guimaraes,Ralph DeMasi,Jain Chung,Miklos Salgo +31 more
TL;DR: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals with OB alone (n = 334) in treatment-experienced HIV-1-infected patients as discussed by the authors.
Journal ArticleDOI
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
Nancie M. Archin,Manzoor Cheema,Daniel C. Parker,Ann Wiegand,Ronald J. Bosch,John M. Coffin,Joseph J. Eron,Myron S. Cohen,David M. Margolis +8 more
TL;DR: The prospective addition of Vpa and RAL, VPA and ENF, or ENF failed to progressively reduce the frequency of RCI, or ablate intermittent and low-level viremia.